Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6839-6846

  Lutgendorf, Susan K ^a,b,c   Lamkin, Donald M ^a   Jennings, Nicholas B ^d   Arevalo, Jesusa M G ^e   Penedo, Frank ^f,h   DeGeest, Koen ^b   Langley, Robert R ^d   Lucci III, Joseph A ^g,h   Cole, Steve W ^e   Lubaroff, David M ^b,c   Sood, Anil K ^d  

^a E11 SSH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Department of Biology   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDANE; GELATINASE A; GELATINASE B; HYDROCORTISONE; NORADRENALIN; VASCULOTROPIN; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFE STRESS; MACROPHAGE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOCIAL SUPPORT; STRUCTURED QUESTIONNAIRE; TUMOR CELL; BEHAVIOR; ENZYMOLOGY; MENTAL STRESS; METABOLISM; MIDDLE AGED; MOOD DISORDER; OVARY TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BEHAVIOR; DEPRESSION; FEMALE; HUMANS; HYDROCORTISONE; MACROPHAGES; MATRIX METALLOPROTEINASES; MIDDLE AGED; MOOD DISORDERS; NOREPINEPHRINE; OVARIAN NEOPLASMS; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL;

EID: 58149269564     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0230     Document Type: Article

References (50)

1. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44.
2. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369-75.
3. Nilsson MB, Armaiz-Pena G, Takahashi R, et al. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a SRC-dependent mechanism. J Biol Chem 2007;282:29919-26.
4. Yang E, Bane CM, MacCallum RC, Kiecolt-Glaser JK, Malarkey WB, Glaser R. Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunol 2002;133:144-50.
5. Yang EV, Sood AK, Chen M, et al. Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66:10357-64.
6. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-21.
7. Lutgendorf SK, Weinrib AZ, Penedo F, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008 Sep 8. [Epub ahead of print].
8. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
10. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002;94:1134-42.
11. Kamat AA, Fletcher MS, Gruman L, et al. The clinical relevance of stromal matrix metalloproteinase (MMP) expression in ovarian cancer. Clin Cancer Res 2006;12:1707-14.
12. Sood AK, Fletcher MS, Coffin JE, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004;190:899-909.
13. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
14. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteinases. Carcinogenesis 2004;25:1543-9.
15. Brown L, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79:233-69.
16. Szelenyi J, Kiss JP, Puskas E, Szelenyi M, Vizi ES. Contribution of differently localized α2- and β-adrenoceptors in the modulation of TNF-α and IL-10 production in endotoxemic mice. Ann NY Acad Sci 2000;917:145-53.
17. Van Miert A. Present concepts on the inflammatory modulators with special reference to cytokines. Vet Res Commun 2002;26:111-26.
18. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002;16:622-53.
19. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann NY Acad Sci 2002;966:290-303.
20. Garcia JJ, del Carmen Saez M, De la Fuente M, Ortega E. Regulation of phagocytic process of macrophages by noradrenaline and its end metabolite 4-hydroxy-3-metoxyphenyl-glycol. Role of α- and β-adrenoreceptors. Mol Cell Biochem 2003;254:299-304.
21. Speidl WS, Toller WG, Kaun C, et al. Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for peri-operative plaque instability. FASEB J 2004;18:603-5.
22. Suarez EC, Lewis J, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 2004;29:119-28.
23. Fricchione G, Bilfinger T, Hartman A, Liu Y, Stefano G. Neuroimmunologic implications in coronary artery disease. Adv Neuroimmunol 1996;6:131-42.
24. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measures 1977;1:385-401.
25. Ensel WM, editor. Measuring depression: the CESD scale. New York: Academic Press; 1986.
26. Cohen S, Kamarck T, Mermelstein R. Global measure of perceived stress. J Health Hum Behav 1983;24:385-96.
27. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979;41:209-18.
28. Andersen B, Farrar WB, Golden-Kreutz D, et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998;90:30-6.
29. Saranson I, Johnson J, Siegel J. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol 1978;46:932-46.
30. Leserman J, Whetten K, Lowe K, Stangl D, Swartz MS, Thielman NM. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. Psychosom Med 2005;67:500-7.
31. Curran SL, Andrykowski MA, Studts JL. Short Form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess 1995;7:80-3.
32. Sacham SA. Shortened version of the Profile of Mood States. J Pers Assess 1983;47:305-6.
33. Russell D, Cutrona C, Rose J, Yurko K. Social and emotional loneliness: an examination of Weiss's typology of loneliness. J Pers Soc Psychol 1984;6:1313-21.
34. Cutrona CE, Russell DW. The provisions of social relationships and adaptation to stress. In: Advances in personal relationships. JAI Press; 1987. p. 37-67.
35. Thaker PH, Yazici S, Nilsson MB, et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 2005;11:4923-33.
36. Weiner H. Perturbing the organism: the biology of stressful experience. Chicago: University of Chicago Press; 1992.
37. Lutgendorf SK, Johnsen EL, Cooper B, et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002;95:808-15.
38. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005;104:305-13.
39. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
40. Bierhaus A, Nawroth PP. Modulation of the vascular endothelium during infection-the role of NF-κB activation. Contrib Microbiol 2003;10:86-105.
41. Morrell EM, Hollandsworth JG. Norepinephrine alterations under stress conditions following the regular practice of meditation. Psychosom Med 1986;48:270-7.
42. Mausbach BT, Dimsdale JE, Ziegler MG, et al. Depressive symptoms predict norepinephrine response to a psychological stressor task in Alzheimer's caregivers. Psychosom Med 2005;67:638-42.
43. Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res 2004;57:353-8.
44. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994;51:411-22.
45. Esler M, Turbott J, Schwarz R, et al. The peripheral kinetics of norepinephrine in depressive illness. Arch Gen Psychiatry 1982;39:295-300.
46. Seeman T, Berkman L, Blazer D, Rowe J. Social ties and support and neuroendocrine function: the MacArthur studies of successful aging. Ann Behav Med 1994;16:95-106.
47. Seeman T, McEwen B. Impact of social environment characteristics on neuroendocrine regulation. Psychosom Med 1996;58:459-71.
48. Deuschle M, Weber B, Colla M, Depner M, Heuser I. Effects of major depression, aging and gender upon calculated diurnal free plasma cortisol concentrations: a re-evaluation study. Stress 1998;2:281-7.
49. Tse WS, Bond AJ. Relationship between baseline cortisol, social functioning and depression: a mediation analysis. Psychiatry Res 2004;126:197-201.
50. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett 1998;435:29-34.